Skip to main content

Eligard (leuprorelin acetate) | For UK Healthcare Professionals

This promotional website has been developed and funded by Recordati Pharmaceuticals Ltd and is only intended for healthcare professionals based in the UK.
Prescribing Information (PI) and Adverse Event (AE) Reporting Information can be accessed via the link found at the bottom of this page.

 TRUST IN OUR SUPPORT

Asset 1

Our priority is to support you

and your patients

ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.1

Choose ELIGARD for your eligible patients with prostate cancer.1

Stable, long-term
ADT patients

  • ADT for 6+ months
  • Low complication risk
  • Fewer injections vs 3-monthly dosing

Patients
with mobility
or access
challenges

  • Frail, elderly
    or rural
  • Fewer injections vs 3-monthly dosing

Men who
need stable
T suppression

  • High-risk disease
  • Stable on 3-month ADT
  • At risk of missed dose rebound

Working-age
men

  • Full-time or
    shift work
  • Minimise time
    off work
  • Convenience
    when travelling

Patients
who want
convenience

  • Fewer injections vs 3-monthly dosing
  • Primary care
    appointments

Patients with
injection anxiety or discomfort

  • Needle-phobic patients
  • Poor IM tolerability
  • Prefers SC route/improved
    experience
  • Primary care
    management

Watch the full ELIGARD

administration video

ADT, androgen deprivation therapy; IM, intramuscular; SC, subcutaneous